{
    "nct_id": "NCT03272919",
    "official_title": "Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy",
    "inclusion_criteria": "* Newly diagnosed stages I to III breast cancer patients with any biomarker status (ER, PR and HER) receiving treatment with platinum-based compounds (Carboplatin and Cisplatin) and/or taxanes (Docetaxel and Paclitaxel).\n* Chemotherapy naive patients with gynecologic cancers including ovarian, uterine, and cervical cancer planning to receive definitive number of platinum-based compounds (carboplatin or cisplatin) and/or taxanes (docetaxel and paclitaxel) chemotherapy.\n* Planned to receive a minimum of 4 cycles of treatment with either of the offending chemotherapy agents (a cycle of weekly paclitaxel is considered 3 doses).\n* Women aged â‰¥ 18 years at signing of informed consent\n* No pre-existing peripheral neuropathy (WPPN)\n* ECOG status 0 or 1\n* Able to provide written, informed consent to participate in the study and follow the study procedures.\n* Cannot participate in another non-medical intervention/therapy for peripheral neuropathy\n* Cannot receive more than 3 weeks of treatment with implicating chemotherapy prior to start of study assigned therapy.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Male\n* Preexisting peripheral neuropathy.\n* Previous exposure to any of the implicated chemotherapy agents within the last 5 years (platinum-based compounds, vinca alkaloids and/or taxanes) that could potentially cause peripheral neuropathy\n* Evidence of significant medical illness, or psychiatric illness/social situation that would, in the investigator's judgment, make the patient inappropriate for this study.\n* Stage IV or metastatic breast cancer\n* Any physical or neurological disability that would preclude patients from participating in physical therapy",
    "miscellaneous_criteria": ""
}